Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer | Zendy

Bala Başak Öven Ustaalıoğlu | Zendy; Ahmet Bılıcı | Zendy; Metin Tilki | Zendy; Ali Sürmelioğlu | Zendy; Burçak Erkol | Zendy; Metin Figen | Zendy; Serab Uyar | Zendy

Open Access

Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer

Author(s) -

Bala Başak Öven Ustaalıoğlu,

Ahmet Bılıcı,

Metin Tilki,

Ali Sürmelioğlu,

Burçak Erkol,

Metin Figen,

Serab Uyar

Publication year - 2018

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.183548

Subject(s) - medicine , capecitabine , regimen , fluorouracil , radiation therapy , chemoradiotherapy , oncology , tolerability , lymph node , surgery , cisplatin , adjuvant therapy , chemotherapy , gastroenterology , cancer , adverse effect , colorectal cancer

Although surgery is considered to be curative treatment, recurrence rates are high in gastric cancer. Adjuvant 5-fluorouracil (5-FU) based chemoradiotherapy has been shown to improve the prognosis. We compared tolerability and efficacy of the two different chemotherapy regimens; 5-FU/leucovorin (LV) versus cisplatin with capecitabine (XP) combined with radiotherapy (RT) in the adjuvant therapy of the lymph node positive locally advanced gastric cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research